Ready To Welcome To...
Health Care: Drugs
Sarepta Therapeutics Inc (SRPT: NASDAQ)
$37.82 -0.12 | -0.32%
05/24/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 37.33M | 46.99M | 29.42M | 17.58M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 37.33M | 46.99M | 29.42M | 17.58M |
| Selling, General, and Administrative Expenses | 14.63M | 16.06M | 14.38M | 8.70M |
| Research & Development | 52.40M | 66.86M | 35.97M | 24.40M |
| Operating Income before D & A (EBITDA) | -29.70M | -35.93M | -20.93M | -15.51M |
| Depreciation & Amortization | 1.52M | 1.30M | 1.46M | 1.38M |
| Interest Income | 354.00K | 677.00K | 259.00K | 0.00 |
| Other Income - Net | -91.94M | 33.02M | -11.50M | -9.20M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -122.81M | -3.53M | -33.64M | -26.08M |
| Interest Expense | 0.00 | 90.00K | 0.00 | 454.00K |
| Pre-Tax Income | -122.81M | -3.62M | -33.64M | -26.54M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -121.29M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -121.29M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -121.29M | -2.32M | -32.18M | -25.16M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-121.29M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -121.29M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -5.14 | -0.12 | -1.74 | -1.62 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -5.14 | -0.12 | -1.74 | -1.62 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -5.14 | -0.12 | -1.74 | -1.62 |
| Basic Normalized Net Income/Share | -5.14 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -5.14 | -0.12 | -1.74 | -1.62 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -5.14 | -0.12 | -1.74 | -1.62 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -5.14 | -0.12 | -1.74 | -1.62 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-5.14 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with SRPT
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserWatch
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- UserKJP Save Stockpickr Fund
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
Latest SRPT Headlines from TheStreet
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner 05.16.13 | 05:05 pm
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Leaders of TheStreet's Drug Approval Contest 05.06.13 | 09:05 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner 05.01.13 | 05:05 pm
- A DMD Expert and Mother Calls For Eteplirsen's Rapid Approval 04.26.13 | 09:04 am
- Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! 04.26.13 | 08:04 am
- Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Laggard 04.19.13 | 05:04 pm
- Stocks Rebound Mirrors Markets After Madrid, London Bombings 04.16.13 | 04:04 pm
- Sarepta Stock Gaps Down On Today's Open (SRPT) 04.16.13 | 09:04 am
Press Releases for SRPT
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
- Over 25 Companies To Present At Emerald Groundhog Day Investment Forum - Business Wire 02.05.13 | 10:02 am
Partner Headlines for SRPT
- Thursday's BioPharma Trade Movers - Seeking Alpha 04.18.13 | 09:04 am
- Muscular Dystrophy Drug Succeeds, Sarepta Buyers Flood In - Seeking Alpha 04.11.13 | 09:04 am
- Barron's Recap (3/23/13): World's Best CEOs - Benzinga 03.24.13 | 01:03 pm
- Sarepta Therapeutics Setting Up For Another Move Upward - Seeking Alpha 01.31.13 | 09:01 am
- Raptor To Rise On Proven Strategy & Upcoming FDA Decision - Seeking Alpha 12.28.12 | 09:12 am
- UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential - Benzinga 11.26.12 | 09:11 am
- Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for Treatment of Duchenne Muscular Dystrophy - Benzinga 10.12.12 | 04:10 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Benzinga Mid-Morning Market Update - Benzinga 10.05.12 | 01:10 pm
- 3 Interesting Moves In Biotech Stocks From Wednesday - Seeking Alpha 10.04.12 | 09:10 am
